- Advertisement -
- Advertisement -

Related

Norron Cheers Hansa Medical Fast Track Designation

Latest Report

- Advertisement -

Stockholm (Hedgenordic) – The share price of Swedish Hansa Medical, a biopharmaceutical company focusing on treatments for rare and severe autoimmune conditions, jumped higher Wednesday morning on the news that the U.S. Food and Drug Administration (FDA) had granted imlifidase Fast Track Designation for the investigation of imlifidase for transplantation.

Among funds having significant holdings in the company is Norron Alpha and Norron Active from Swedish hedge fund manager Norron. According to Morningstar, Hansa Medical has a portfolio weight of 4.3 percent in the two respective funds.

In a comment to the news, Gustaf Sjögren (pictured), portfolio manager at Norron says:

“The news from Hansa today, that a fast track designation has been granted by the FDA, is positive and means that they will speed up the process as the treatment is believed to be important enough. This does not mean that the probability of the treatment being approved is higher, but it is already within the 80-85 percent probability range.”

“We hope that today´s news will shorten the approval process by a number of months, meaning  that the company will have a drug ready for the market by Q4 2019.”

Hansa Medical trades 7 percent higher by midday Wednesday at SEK 330 per share, having traded as high as SEK 343 per share earlier in the session.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

HedgeNordic Editorial Team
HedgeNordic Editorial Team
This article was written, or published, by the HedgeNordic editorial team.

Latest Articles

Quirky Questions for Dr. Alexander Mende (RPM)

Not every conversation in the hedge fund world needs to revolve around trend signals, Sharpe ratios, or manager due diligence. In HedgeNordic’s ongoing Quirky...

Elementa Tops Swedish Hedge Fund Universe in H1

After celebrating its ten-year anniversary in March, long/short equity fund Elementa closed the first half of 2025 as the best-performing Swedish hedge fund, delivering...

Asgard Winds Down Macro Strategy, Refocuses on Fixed Income

Less than a year after the launch of Asgard-Steno Global Macro Fund – a collaborative effort between macro strategist Andreas Steno Larsen and fixed-income...

Eric Strand’s Green-Gold 60/40 Alternative Roars Back to Life

After a two-and-a-half-year drought, including a rough start to 2025, AuAg Precious Green has taken off in recent months. The fund, Eric Strand’s innovative...

BNY Debuts Tail-Risk Overlay Fund

BNY Investments Newton, the specialist multi-asset and equity management arm of BNY Mellon, has launched the BNY Adaptive Risk Overlay Fund – a tail-hedging...

Taiga Fund Delivers Best First Half Since 2019

Usually operating under the radar, Norwegian long/short equity vehicle Taiga Fund delivered one of its strongest first-half performances to date – its best since...

Allocator Interviews

In-Depth: High Yield

Voices

Request for Proposal

- Advertisement -
HedgeNordic
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.